相似文献
1
Intravitreal therapy for the management of diabetic retinopathy: A concise review.
World J Exp Med. 2024 Dec 20;14(4):99235. doi: 10.5493/wjem.v14.i4.99235.
2
Efficacy and safety of intravitreal anti-VEGF therapy in diabetic retinopathy: what we have learned and what should we learn further?
Expert Opin Biol Ther. 2022 Oct;22(10):1275-1291. doi: 10.1080/14712598.2022.2100694. Epub 2022 Jul 17.
3
Anti-VEGF drugs compared with laser photocoagulation for the treatment of proliferative diabetic retinopathy: a systematic review and individual participant data meta-analysis.
Health Technol Assess. 2025 Apr 2:1-75. doi: 10.3310/MJYP6578.
4
Standard threshold laser versus subthreshold micropulse laser for adults with diabetic macular oedema: the DIAMONDS non-inferiority RCT.
Health Technol Assess. 2022 Dec;26(50):1-86. doi: 10.3310/SZKI2484.
5
[Combination therapy in patients with concomitant macular edema and proliferative diabetic retinopathy].
Vestn Oftalmol. 2019;135(6):67-72. doi: 10.17116/oftalma201913506167.
6
The Evolving Treatment of Diabetic Retinopathy.
Clin Ophthalmol. 2020 Mar 4;14:653-678. doi: 10.2147/OPTH.S236637. eCollection 2020.
7
Intravitreal Anti-Vascular Endothelial Growth Factor Agents for the Treatment of Diabetic Retinopathy: A Review of the Literature.
Pharmaceutics. 2021 Jul 26;13(8):1137. doi: 10.3390/pharmaceutics13081137.
8
Vascular endothelial growth factor and diabetic macular edema.
Surv Ophthalmol. 2016 Nov-Dec;61(6):759-768. doi: 10.1016/j.survophthal.2016.03.010. Epub 2016 Apr 1.
9
Association of Intravitreal Aflibercept With Optical Coherence Tomography Angiography Vessel Density in Patients With Proliferative Diabetic Retinopathy: A Secondary Analysis of a Randomized Clinical Trial.
JAMA Ophthalmol. 2020 Aug 1;138(8):851-857. doi: 10.1001/jamaophthalmol.2020.2130.
10
Anti-vascular endothelial growth factor therapy for diabetic macular edema.
Ther Adv Endocrinol Metab. 2013 Dec;4(6):151-69. doi: 10.1177/2042018813512360.
本文引用的文献
1
Comparing the efficacy of glucocorticoids and anti-VEGF in treating diabetic macular edema: systematic review and comprehensive analysis.
Front Endocrinol (Lausanne). 2024 Mar 22;15:1342530. doi: 10.3389/fendo.2024.1342530. eCollection 2024.
2
Real-World Experience with Brolucizumab Compared to Aflibercept in Treatment-Naïve and Therapy-Refractory Patients with Diabetic Macular Edema.
J Clin Med. 2024 Mar 21;13(6):1819. doi: 10.3390/jcm13061819.
3
Review of real-world evidence of dual inhibition of VEGF-A and ANG-2 with faricimab in NAMD and DME.
Int J Retina Vitreous. 2024 Jan 17;10(1):5. doi: 10.1186/s40942-024-00525-9.
4
Functional Outcomes of Brolucizumab-Induced Intraocular Inflammation Involving the Posterior Segment-A Meta-Analysis and Systematic Review.
J Clin Med. 2023 Jul 14;12(14):4671. doi: 10.3390/jcm12144671.
5
KESTREL and KITE Phase 3 Studies: 100-Week Results With Brolucizumab in Patients With Diabetic Macular Edema.
Am J Ophthalmol. 2024 Apr;260:70-83. doi: 10.1016/j.ajo.2023.07.012. Epub 2023 Jul 15.
6
Diabetes more than retinopathy, it's effect on the anterior segment of eye.
World J Clin Cases. 2023 Jun 6;11(16):3736-3749. doi: 10.12998/wjcc.v11.i16.3736.
7
Aflibercept for long-term treatment of diabetic macular edema and proliferative diabetic retinopathy: a meta-analysis.
Front Endocrinol (Lausanne). 2023 May 16;14:1144422. doi: 10.3389/fendo.2023.1144422. eCollection 2023.
8
Four-Year Visual Outcomes in the Protocol W Randomized Trial of Intravitreous Aflibercept for Prevention of Vision-Threatening Complications of Diabetic Retinopathy.
JAMA. 2023 Feb 7;329(5):376-385. doi: 10.1001/jama.2022.25029.
9
Everything real about unreal artificial intelligence in diabetic retinopathy and in ocular pathologies.
World J Diabetes. 2022 Oct 15;13(10):822-834. doi: 10.4239/wjd.v13.i10.822.
10
The efficacy and safety of intravitreal injection of Ranibizumab as pre-treatment for vitrectomy in proliferative diabetic retinopathy with vitreous hemorrhage.
BMC Ophthalmol. 2022 Feb 10;22(1):63. doi: 10.1186/s12886-022-02303-3.
Zotero 插件
